Year All202620252024202320222021202020192018 June 3, 2026 Gossamer Bio, Inc. Announces Early Tender Results and Early Settlement for Exchange Offer and Consent Solicitation with Respect to Existing Convertible Notes June 2, 2026 Gossamer Bio, Inc. Announces Extension of Early Tender Date for Exchange Offer and Consent Solicitation with Respect to Existing Convertible Notes May 18, 2026 Gossamer Bio, Inc. Launches Exchange Offer and Consent Solicitation Intended to Eliminate Over $120 Million of Debt with Existing Noteholder Support May 18, 2026 Gossamer Bio Announces First Quarter 2026 Financial Results and Provides Business Update May 15, 2026 Gossamer Bio to Announce First Quarter 2026 Financial Results and Host Conference Call and Webcast on May 18, 2026 March 17, 2026 Gossamer Bio Announces Fourth Quarter and Full-Year 2025 Financial Results and Provides Corporate Update February 23, 2026 Gossamer Bio Announces Topline Results from the Phase 3 PROSERA Study Evaluating Seralutinib in Pulmonary Arterial Hypertension January 8, 2026 Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Year All202620252024202320222021202020192018 June 3, 2026 Gossamer Bio, Inc. Announces Early Tender Results and Early Settlement for Exchange Offer and Consent Solicitation with Respect to Existing Convertible Notes June 2, 2026 Gossamer Bio, Inc. Announces Extension of Early Tender Date for Exchange Offer and Consent Solicitation with Respect to Existing Convertible Notes May 18, 2026 Gossamer Bio, Inc. Launches Exchange Offer and Consent Solicitation Intended to Eliminate Over $120 Million of Debt with Existing Noteholder Support May 18, 2026 Gossamer Bio Announces First Quarter 2026 Financial Results and Provides Business Update May 15, 2026 Gossamer Bio to Announce First Quarter 2026 Financial Results and Host Conference Call and Webcast on May 18, 2026 March 17, 2026 Gossamer Bio Announces Fourth Quarter and Full-Year 2025 Financial Results and Provides Corporate Update February 23, 2026 Gossamer Bio Announces Topline Results from the Phase 3 PROSERA Study Evaluating Seralutinib in Pulmonary Arterial Hypertension January 8, 2026 Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
